Есть ли место муколитикам в программе лечения хронической обструктивной болезни легких?


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

В статье рассматривается современная концепция патогенеза гиперпродукции бронхиальной слизи при хронической обструктивной болезни легких. Описывается симптоматика ХОБЛ: кашель, экспекторация мокроты и эпизодические обострения, наиболее характерные для бронхитического фенотипа. Дана оценка тесной связи гиперпродукции БС, мукостаза, развития обострений (в т.ч. инфекционных) и прогрессирования заболевания. Приведена современная классификация мукоактивных препаратов. Обсуждается вопрос эффективности мукоактивных препаратов при хронической обструктивной болезни легких (антиоксидантное действие и/или муколитическое). Особое внимание привлекает ацетилцистеин - активный муколитик и мощный антиоксидант.

Полный текст

Доступ закрыт

Об авторах

И. Л Клячкина

Российская медицинская академия непрерывного профессионального образования

Email: formozailk2012@yandex.ru
к.м.н., доцент кафедры пульмонологии

Список литературы

  1. Button B, Goodell H.P, Atieh E., et al. Roles of mucus adhesion and cohesion in cough clearance. Proc Natl Acad Sci USA. 2018;115:12501-506. Doi: 10.1073/ pnas.1811787115.
  2. Okuda K., Chen G., Subramani D.B., et al. Localization of secretory mucins MUC5AC and MUC5B in normal/ healthy human airways. Am J Respir Crit Care. 2019;199(6):715-27. doi: 10.1164/rccm.201804-Q734OC.
  3. Widdicombe J.H., Wine J.J. Airway gland structure and function. Physiol Rev 2015;95:1241-319. doi: 10.1152/physrev.00039.2014.
  4. Henderson A.G., Ehre C., Button B., et al. Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure. J Clin Invest. 2014;124:3047-60. doi: 10.1172/JCI73469.
  5. Kesimer M., Ford A.A., Ceppe A., et al. Airway mucin concentration as a marker of chronic bronchitis. N Engl J Med. 2017;377:911-22. Doi: 10.1056/ NEJMoa1701632.
  6. Button B., Cai L.H., Ehre C., et al. A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia. Science. 2012;337:937-41. doi: 10.1126/sdence.1223012.
  7. Boucher R.C. Human airway ion transport: part one. Am J Respir Crit Care Med. 1994;150:271-81. doi: 10.1164/ajrccm.150.1.8025763.
  8. Fahy J.V, Dickey B.F. Airway mucus function and dysfunction. N Engl J Med. 2010;363:2233-247. doi: 10.1056/NEJMra0910061.
  9. Button B, Okada S.F, Frederick C.B., et al. Mechanosensitive ATP release maintains proper mucus hydration of airways. Sci Signal. 2013;6:ra46-ra46. doi: 10.1126/scisignal.2003755.
  10. Richard C, Boucher, M.D. Muco-Obstructive Lung Diseases N Engl J Med. 2019;380:1941-53. doi: 10.1056/NEJMra1813799.
  11. Leith D.E. Cough. Phys Ther. 1968;48:439-47. doi: 10.1093/ptj/48.5.439
  12. Cole A.M., Liao H.I., Stuchlik O., et al. Cationic polypeptides are required for antibacterial activity of human airway fluid. J Immunol 2002;169:6985-91. Doi: https://doi.org/10.4049/jimmunol. 169.12.6985.
  13. Livraghi-Butrico A., Grubb B.R., Wilkinson K.J., et al. Contribution of mucus concentration and secreted mucins Muc5ac and Muc5b to the pathogenesis of muco-obstructive lung disease. Mucosal Immunol. 2017;10:395-407.
  14. Sethi S., Maloney J., Grove L., et al. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173:991-98.
  15. Lee A.L., Button B.M., Denehy L, et al. Proximal and distal gastro-oesophageal reflux in chronic obstructive pulmonary disease and bronchiectasis. Respirology. 2014;19:211-17. doi: 10.1111/resp.12182.
  16. Segal L.N., Clemente J.C., Tsay J.C., et al. Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a Th17 phenotype. Nat Microbiol. 2016;1:16031-31. Doi: 10.1038/ nmicrobiol.2016.31.
  17. Boucher R.C. On the pathogenesis of acute exacerbations of mucoobstructive lung diseases. Ann Am Thorac Soc. 2015;12:S160-S163. Doi: 10.1513/ AnnalsATS.201507-460AW.
  18. Han M.K, Agusti A., Calverley PM., et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010;182:598-604. doi: 10.1164/rccm.200912-1843CC.
  19. Barnes PJ., D.Sc. Chronic Obstructive Pulmonary Disease. N Engl J Med. 2000;343:269-80.
  20. Hogg J.C., Pare PD., Hackett T.L. The contribution of small airway obstruction to the pathogenesis of chronic obstructive pulmonary disease. Physiol Rev. 2017;97:529-52. Doi: 10.1152/ physrev.00025.2015.
  21. Rogers D.F. Mucoactive agents for airway mucus hypersecretory diseases. Respir Care. 2007, 52:1176-93.
  22. Burgel PR., Nesme-Meyer P, Chanez P, et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest. 2009;135:975-82. Doi: 10.1378/ chest.08-2062.
  23. Speizer F.E., Fay M.E., Dockery D.W., et al. Chronic obstructive pulmonary disease mortality in six U.S. cities. Am Rev Respir Dis. 1989;140(3):49-55. doi: 10.1164/ajrccm/140.3_Pt_2.S49.
  24. Prescott E., Lange P., Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J. 1995;8:1333-38. doi: 10.1183/09031936.95.08081333.
  25. Vestbo J., Prescott E., Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med. 1996;153:1530-35.
  26. Balsamo R., Lanata L., Egan C.G. Mucoactive drugs. Eur Respir Rev. 2010;19(116):127-33. doi: 10.1183/09059180.00003510.
  27. Boman G., Backer U., Larsson S., et al. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis. 1983;64(6): 405-15.
  28. Aruoma O.I., Halliwell B., Hoey B.M., Butler J. The antioxidant action of N-acetylcysteine:its reaction with hydrogen peroxide and hypochlorous acid. Free Radic Biol Med. 1989;6(6):593-97. doi: 10.1016/0891-5849(89)90066-x.
  29. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. (Based on an April 1998 NHLBI/WHO Workshop) Report. Publication 2701. 2001.
  30. Grassi C., Morandini G.C. A controlled trial of intermit tent oral acetylcysteine in the longterm treatment of chronic bronchitis. Eur J Clin Pharmacol. 1976;9(5-6):393-96. doi: 10.1007/bf00606554.
  31. Hansen N.C., Skriver A., Brorsen Riis L., et al. Orally administered N-acetylcysteine may improve general wellbeing in patients with mild chronic bronchitis. Respir Med. 1994;88(7):531-35. doi: 10.1016/s0954-6111(05)80337-3.
  32. Pela R., Calcagni A.M., Subiaco S., et al. N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration. 1999;66(6):495-500. doi: 10.1159/000029447.
  33. Decramer M., Rutten-van- Molken M., Dekhuijzen P.N.R., et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet. 2005;365:1552-60.
  34. Zheng J.P, Wen F.Q., Bai C.X., et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2014;2(3):187-94. Doi: 10.1016/ S2213-2600(13)70286-8.
  35. Miravitlles M., Soler-Catabha J.J., Calle M., et al. Spanish Society of Pulmonology and Thoracic Surgery Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery Arch Bronconeumol. 2012;48(7):247-57. Doi: 10.1016/j. arbres.2012.04.001.
  36. Criner G.J., Bourbeau J., Diekemper R.L., et al. Prevention of acute exacerbations of COPD: American College of ChestPhysiciansandCanadianThoracicSocietyGuideline. Chest. 2015;147(4):895-942. Doi: 10.1378/ chest.14-1676.
  37. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019. Available from: http://www.goldcopd.org/

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2019